Company & Sponsor Intelligence
UCB Pharma SA
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials4
Recruiting0
Completed3
Countries3
Therapeutic footprint
epilepsyparkinsons
Indexed studies
NCT01710657A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures
epilepsy · ChinaPHASE3
epilepsy · ChinaPHASE3
NCT01728077Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy
epilepsy · United StatesPHASE3
epilepsy · United StatesPHASE3
NCT01653262Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
epilepsy · United StatesPHASE3
epilepsy · United StatesPHASE3
NCT01519882Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease
parkinsons · United KingdomPHASE4
parkinsons · United KingdomPHASE4
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →